Skip to main content
. Author manuscript; available in PMC: 2013 Feb 7.
Published in final edited form as: J Am Coll Cardiol. 2012 Feb 7;59(6):616–626. doi: 10.1016/j.jacc.2011.10.881

Table 1.

Overview of all in vivo studies

Study Description # apoE−/− mice # LDLR−/− mice # WT mice
pKa Blood drawn over a 24 hour time period in n=3/formulation.
Untargeted, MDA2 and IK17 Mn(II) formulations tested		 9 9
Biodistribution Tissue excised after 24, 48, 72, 96 and 1 wk injection. N=3 formulation/time point.
Untargeted, MDA2 and IK17 Mn(II) formulations tested.		 45
Neurotoxicity MR imaging and brain uptake of targeted and MDA2 micelles (n=3/formulation) 6
MR Imaging in apoE−/− mice MR imaging performed over a 1 wk time interval post injection (n=8/formulation).
Untargeted, MDA2 and IK17 Mn(II) formulations tested. MDA2 Gd (III) micelles re-tested.		 32
Competitive inhibition MR imaging performed over a 1 wk time interval post injection (n=3/formulation).
Only MDA2 Mn(II) formulation tested.		 3
MR Imaging in LDLR−/− mice MR imaging performed over a 1 wk time interval post injection (n=8/formulation).
Only untargeted and MDA2 Mn(II) formulations tested.		 16